Latest Sales Pipeline News

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

Securelink Networks has increased its stake in the PT&T joint venture to 50.1%, securing effective control, while its VSN Plus product gains strong traction in the Philippine market. The company also advances its ASX re-listing efforts amid ongoing cost reductions.

AVADA Group Limited reported a robust 24% increase in cash receipts for Q2 FY26, driven by strong sales and strategic leadership changes, while expanding its trade finance facility to support ongoing growth.

Oldfields Holdings reports steady progress in its turnaround strategy, cutting costs and reallocating assets to stronger regions while preparing for a capital raise and potential acquisitions.

GreenHy2 Limited has reported its first revenue from sodium-ion battery sales alongside a robust $2 million residential sales pipeline, while advancing strategic partnerships and certification efforts to accelerate market adoption.

Pure One Corporation Limited has advanced its zero-emission mobility strategy with a new local vehicle assembly partnership, expanded US hydrogen market collaborations, and progressed the spin-out of its Australian gas assets via Eastern Gas IPO.

Identitii Limited has secured five new customer contracts worth $250k and seen a four-fold increase in usage of its BNDRY platform, even as its capital raising efforts face delays due to a Takeovers Panel application.

IMEXHS Limited has reported a strong finish to FY25, delivering revenue and underlying EBITDA at the top end of its guidance, driven by robust software growth and expanding recurring revenue.

Adheris Health reported a sharp decline in Q2 FY26 revenue but is pushing ahead with leadership changes, cost cuts, and a new digital platform to reshape its future.

AdNeo Limited reported a striking 89% increase in customer receipts in Q2 FY26, driven by recent acquisitions and strong contract wins, edging close to cash flow positivity. The company’s strategic cost reductions and expanding sales pipeline signal promising momentum for the remainder of the year.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.